GSK Plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
4.8%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$45.7Bnext fiscal year
FY EPS (est.)
$6.40next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 28 Oct 2026 |
| Q4 2026 & Full Year Earnings Release | 3 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Specialty Medicines Sales Growth (CER) Quarterly14.0%Target: Double-digit growth to support 2031 sales outlook
Vaccines Sales Growth (CER) Quarterly8.0%Target: Mid-to-high single digit growth
Phase III Trial Starts in 2026 Annually20.0Target: 20+
Annual Cost Savings by 2029 AnnuallyTarget: £1.9 billion
Watch Items
- Dolutegravir (HIV) Patent ExpiryTrigger: Loss of exclusivity period (2028-2030)Action: Monitor market share erosion and offset with Specialty Medicines and Vaccines growth
- Late-Stage Pipeline AccelerationTrigger: 7 key assets across 18 indications in Oncology, Respiratory, Hepatology, and VaccinesAction: Track clinical trial readouts and regulatory filings
Research as of 2 Sep 2026